2030 年阿尔茨海默病药物市场报告(按细分市场、地域、动态、最新发展和战略见解)

  • Report Code : TIPRE00015800
  • Category : Life Sciences
  • No. of Pages : 150
Buy Now

Alzheimer’s Drugs Market Share, Growth, & Report by 2030

Buy Now

【研究报告】阿尔茨海默病药物市场预计将从2022年的62.1亿美元增长到2030年的220.1亿美元;预计 2022 年至 2030 年复合年增长率为 17.1%。
市场洞察和分析师观点:
阿尔茨海默病 (AD) 是一种由神经元进行性死亡引起的神经系统疾病。症状逐渐出现,并可能导致痴呆。虽然这种情况无法完全治愈,但有药物可以暂时缓解症状并减缓疾病的进展。 AD 的高患病率,特别是在老年人群中,以及制药行业不断增加的针对该疾病的诊断和治疗的研发活动,是推动阿尔茨海默病药物市场增长的关键因素。然而,药物的副作用和严格的监管环境阻碍了市场的进步。此外,对 AD 个性化治疗和精准药物的日益关注预计将在未来几年带来新的阿尔茨海默病药物市场趋势。
增长驱动因素和限制:
AD 和相关痴呆症病例的不断增加推动了阿尔茨海默氏症药物市场规模。阿尔茨海默病是全世界最常见的痴呆症,占所有病例的 60-70%。它是一种进行性神经退行性疾病,多年来逐渐恶化,在老龄化人群中更为常见。根据世界卫生组织 (WHO) 2022 年 10 月发布的报告,到 2030 年,全球 60 岁及以上人口将增长到 14 亿,到 2050 年将达到 21 亿。预计不断增长的老年人口将增加疾病负担,促进未来几年对相关医疗的需求。
此外,人们对 AD 认识的提高、诊断率的提高以及对新疗法开发的投资增加是市场增长的推动因素。根据阿尔茨海默病协会 2021 年发布的报告,该协会在 2020 年投资了 6300 万美元,用于推进阿尔茨海默病和痴呆症研究。
然而,潜在的副作用对阿尔茨海默病药物市场的发展具有重大影响。乙酰胆碱酯酶抑制剂 (AChEI) 和 NMDA 受体拮抗剂是治疗 AD 的常用药物。尽管这些药物被广泛使用,并且按照指示使用通常被认为是安全的,但一些特定的副作用和担忧与它们的使用有关。与 AD 药物相关的最显着的不良反应是服用过量或使用不当时出现的头晕、恶心、腹泻和腹痛。这是一个主要问题,可能会影响消费者对产品的信心,可能导致使用量减少。根据《ScienceDirect Journal》2021 年发表的一篇文章,评估用于治疗 AD 的药物不良反应的研究报告了与 AChEI 相关的心脏不良事件以及与 AChEI 相关的胃肠道副作用,如便秘、腹泻、呕吐和腹痛。美金刚。因此,这些药物的副作用阻碍了阿尔茨海默氏症药物市场。

报告细分和范围:
“阿尔茨海默氏症药物市场分析”已通过考虑以下细分进行:药物类别和分销渠道。
细分分析:
根据药物类别,市场分为胆碱酯酶抑制剂、NMDA 受体拮抗剂、组合药物和管道药物。胆碱酯酶抑制剂细分市场在 2022 年占据了最大的阿尔茨海默病药物市场份额。预计管道药物细分市场在 2022 年至 2030 年期间复合年增长率最高。胆碱酯酶抑制剂部分进一步细分为多奈哌齐、加兰他敏和卡巴拉汀。胆碱酯酶抑制剂是由精神科医生或神经科医生等专家针对早中期 AD 开出的处方。这些药物可以提高大脑中乙酰胆碱的水平,乙酰胆碱是一种帮助神经细胞相互沟通的神经递质。
根据分销渠道,市场分为医院药房、零售药房和在线药房。 2022年,医院药房部门拥有最大的阿尔茨海默病药物市场份额。预计在线药店领域在 2022 年至 2030 年期间复合年增长率最高。
阿尔茨海默氏症药物市场,按分销渠道 - 2022 年和 2030 年
区域分析:
阿尔茨海默氏症药物市场报告的范围涉及北美、欧洲、亚太地区、南美洲和中美洲以及中东和非洲非洲。 2022年,由于制药公司开展广泛的研发活动,以及该地区人口老龄化中 AD 和相关痴呆症的流行,北美将占据全球市场的最大份额。据阿尔茨海默病协会称,到 2023 年,美国将有超过 600 万人被诊断患有阿尔茨海默病,而 65 岁或以上的老年人中约有九分之一(占美国人口的 10.7%)患有阿尔茨海默病。此外,根据美国疾病控制与预防中心(CDC)2020年10月提供的统计数据,AD是美国成年人第六大死因。此外,美国各地医疗保健服务支出的增加增加了对 AD 治疗药物的需求,有利于该地区阿尔茨海默病药物市场的增长。
行业发展和未来机遇:
阿尔茨海默病药物市场预测可以帮助利益相关者这个市场计划他们的增长战略。以下列出了全球阿尔茨海默氏症药物市场主要参与者采取的一些举措:
2024 年 1 月,卫材株式会社和百健公司宣布,其合作开发的 LEQEMBI 已在中国。它是一种人源化、抗可溶性聚集淀粉样蛋白-β(Aβ)单克隆抗体,开发用于治疗 AD 所致的轻度认知障碍(MCI)和轻度 AD 痴呆。 2023 年 5 月,大冢制药有限公司与 Lundbeck LLC 合作礼来公司宣布,他们合作开发的含有 brexpiprmaze 的 REXULTI 补充新药申请 (sNDA) 已获得美国食品和药物管理局 (FDA) 批准,用于治疗阿尔茨海默氏症和痴呆症的神经精神症状。 2023 年 5 月,礼来公司宣布其阿尔茨海默病药物 Donanemab 的 TRAILBLAZER-ALZ 2 3 期研究取得积极结果。根据该研究,Donanemab 显着减缓了早期症状性 AD 患者的认知和功能下降。 2022 年 9 月,Corium, Inc. 在美国推出了 ADLARITY,这是一种多奈哌齐透皮系统。它是一种处方药,旨在治疗 AD 患者的轻度、中度或重度痴呆症。这种透皮系统是第一个也是唯一一个每周一次的贴剂,可通过皮肤提供一致剂量的多奈哌齐,并且没有胃肠道副作用。竞争格局和主要公司:
辉瑞公司;西门子医疗保健有限公司;梯瓦制药工业有限公司;葛兰素史克公司;赛诺菲;诺华公司;阿斯利康;艾伯维公司;卫材有限公司;和武田制药有限公司是阿尔茨海默病药物市场报告中介绍的知名参与者之一。此外,研究期间还对其他几家参与者进行了研究和分析,以全面了解市场及其生态系统。
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What factors drive the Alzheimer’s drugs market?

Key factors driving the Alzheimer’s drugs market growth include the high prevalence of AD, particularly in the senior population, and growing research and development activities in the pharmaceutical industry to introduce diagnostics and therapies for the condition.

What was the estimated Alzheimer’s drugs market size in 2022?

The Alzheimer’s drugs market was valued at US$ 6.21 billion in 2022.

What are the growth estimates for the Alzheimer’s drugs market till 2030?

The Alzheimer’s drugs market is expected to be valued at US$ 22.01 billion in 2030.

What drugs are indicated for Alzheimer’s disease?

Alzheimer's disease (AD) is a neurological disorder caused by the progressive death of neurons. The symptoms begin gradually and can lead to dementia. Although the condition cannot be cured completely, there are medicines available that can temporarily alleviate the symptoms and slow down the progression of the disease. Drugs from the class of cholinesterase inhibitors, NMDA receptor antagonists, and combination of these two are indicated for AD.

Which product segment dominates the Alzheimer’s drugs market?

The Alzheimer’s drugs market, by drug class, is segmented into cholinesterase inhibitors, NMDA receptor antagonists, combination drugs, and pipeline drugs. The cholinesterase inhibitors segment held a larger market share in 2022. The pipeline drugs segment is anticipated to register a higher CAGR during 2022-2030.

Who are the major players in the Alzheimer’s drugs market?

The Alzheimer’s drugs market majorly consists of the players such as Pfizer Inc.; Siemens Healthcare GmbH; Teva Pharmaceutical Industries Ltd.; GlaxoSmithKline plc; Sanofi; Novartis AG; AstraZeneca; AbbVie Inc.; Eisai Co., Ltd.; and Takeda Pharmaceutical Company Limited.

The List of Companies - Alzheimer’s Drugs Market

  1. Pfizer Inc.
  2. Siemens Healthcare GmbH
  3. Teva Pharmaceutical Industries Ltd.
  4. GlaxoSmithKline plc
  5. Sanofi
  6. Novartis AG
  7. AstraZeneca
  8. AbbVie Inc.
  9. Eisai Co., Ltd.
  10. Takeda Pharmaceutical Company Limited  

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to Life Sciences : READ MORE..